Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7280636 | Brain, Behavior, and Immunity | 2015 | 9 Pages |
Abstract
We therefore developed in vivo and in vitro models of post-fingolimod MS rebound to unravel its cellular and molecular mechanisms. The impact of fingolimod withdrawal on T regulatory lymphocytes was also investigated by means of cytofluorimetric analysis and antigen-specific lymphocyte proliferation assays. We show that mice with relapsing-remitting experimental autoimmune encephalomyelitis (EAE) undergo extremely severe, chronic disease rebound upon discontinuation of fingolimod. Remarkably, rebound is preceded by a burst of S1P1 overexpression in lymph node-entrapped lymphocytes that correlates with subsequent massive lymphocyte egress and widespread CNS immune infiltration. Also, consistent with the ability of S1P1 to counteract polarization and function of T regulatory lymphocytes their number and suppression of effector T cells is reduced by fingolimod suspension. Data disclose the first pathogenic mechanisms of post-fingolimod rebound that may be targeted for therapeutic intervention.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Leonardo Cavone, Roberta Felici, Andrea Lapucci, Daniela Buonvicino, Sara Pratesi, Mirko Muzzi, Bahia Hakiki, Laura Maggi, Benedetta Peruzzi, Roberto Caporale, Francesco Annunziato, Maria Pia Amato, Alberto Chiarugi,